A Duchenne Breakthrough Awaits In 2023 - But Risks Remain For Sarepta And US FDA

Gene Therapy Could Be Launched Mid-2023

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.